항염증제 시장 규모, 점유율, 성장, 세계 산업 분석, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of anti-inflammatory drugs Market

The global anti-inflammatory drugs market size was valued at USD 145.05 billion in 2025 and is projected to reach USD 159.26 billion in 2026 and USD 336.45 billion by 2034. The market is driven by the rising prevalence of inflammatory and autoimmune diseases, increasing adoption of biologics and biosimilars, and growing preference for non-opioid therapies. North America dominated the market with a 44.09% share in 2025, supported by strong biologics adoption, research investments, and favorable healthcare policies.

Market Definition and Scope

Anti-inflammatory drugs are therapeutic products used to reduce inflammation and manage pain associated with autoimmune, respiratory, musculoskeletal, and other diseases. The market includes anti-inflammatory biologics, non-steroidal anti-inflammatory drugs (NSAIDs), and corticosteroids. These therapies are administered through oral, injection, inhalation, and topical routes and are distributed through hospital, retail, and online pharmacies.

Market Trends

A major trend shaping the anti-inflammatory drugs market is the growing development and commercialization of biosimilars. The expiration of patents for leading biologics has encouraged pharmaceutical companies to develop biosimilar versions of established therapies, particularly adalimumab, infliximab, and etanercept. Increasing acceptance of biosimilars can improve treatment accessibility while creating competition for originator drugs. At the same time, pharmaceutical companies are investing in advanced biologics targeting TNF, interleukins, and Janus kinase pathways.

Market Dynamics

DRIVER - Rising Prevalence of Inflammatory Diseases: Increasing cases of rheumatoid arthritis, psoriasis, inflammatory bowel diseases, ulcerative colitis, asthma, COPD, and atopic dermatitis are creating sustained demand for anti-inflammatory therapies. Growing healthcare awareness and diagnosis rates are also encouraging treatment adoption.

MARKET OPPORTUNITY - Advanced Biologics and Pipeline Drugs: Research into monoclonal antibodies, TNF inhibitors, interleukins, and other targeted therapies is creating significant opportunities. New products and pipeline candidates can address unmet treatment requirements across autoimmune and inflammatory diseases.

RESTRAINT - Side Effects of NSAIDs: Although NSAIDs are widely used, prolonged or inappropriate use can result in gastrointestinal complications, stomach ulcers, allergic reactions, dizziness, stomach pain, and GI bleeding. These safety concerns can influence prescribing patterns and increase healthcare costs.

Segmentation Analysis

By Drug Class: Anti-inflammatory biologics represent the leading segment, supported by strong sales of biologic therapies, increasing monoclonal antibody adoption, and biosimilar launches. NSAIDs continue to benefit from their broad use for pain and inflammation, while corticosteroids remain important for respiratory and inflammatory conditions.

By Application: Autoimmune inflammatory diseases constitute the leading application segment due to the growing prevalence of rheumatoid arthritis, psoriasis, and inflammatory bowel diseases. Respiratory diseases are also generating demand because of increasing COPD cases and corticosteroid use.

By Route of Administration: Injection is a leading route because many biologic therapies are administered through injections. Oral therapies maintain strong demand because of their convenience and widespread availability, while inhaled and topical treatments support specific respiratory and localized inflammatory conditions.

By Distribution Channel: Hospital pharmacies hold a major position due to prescription volumes and treatment of chronic inflammatory diseases. Retail pharmacies benefit from OTC products such as ibuprofen and diclofenac, while online pharmacies are expanding with increasing e-commerce adoption and consumer convenience.

Regional Insights

North America: North America generated a market value of USD 41.39 billion in 2025, making it the dominant regional market. Strong biologics adoption, biosimilar development, research investment, and demand for non-opioid pain treatments support growth.

Europe: Europe is witnessing strong development due to favorable reimbursement policies and increasing availability of biosimilars. The introduction of adalimumab biosimilars is strengthening treatment accessibility and competition.

Asia Pacific: Asia Pacific is expanding through greater OTC drug adoption, increasing demand for generic NSAIDs and corticosteroids, and a growing geriatric population. Improving healthcare infrastructure is also supporting market development.

U.S. and Japan: The U.S. benefits from strong biologics adoption and established pharmaceutical infrastructure, while Japan's aging population and increasing burden of inflammatory diseases are supporting therapeutic demand.

Competitive Landscape

The market is competitive and includes major pharmaceutical companies such as AbbVie Inc., Merck & Co., Inc., Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., Pfizer Inc., Novartis AG, GlaxoSmithKline plc., Eli Lilly and Company, Amgen Inc., and Biogen. AbbVie has historically maintained a strong position through Humira, while Johnson & Johnson has benefited from products such as Remicade, Stelara, and Simponi. Biosimilar competition is increasingly influencing the competitive environment.

Key Industry Developments

In December 2019, UCB S.A. announced positive Phase 3 results for Bimekizumab for psoriasis treatment. In August 2019, AbbVie launched RINVOQ, a Janus kinase inhibitor for rheumatoid arthritis. In October 2018, Amgen launched Amgevita, an adalimumab biosimilar in Europe. In April 2018, Strides Pharma received U.S. FDA approval for Ibuprofen OTC Capsules.

Report Coverage

The Anti-Inflammatory Drugs Market Report covers market size, market value, growth drivers, trends, restraints, opportunities, segmentation, regional analysis, competitive landscape, and key industry developments. The report evaluates drug class, application, route of administration, and distribution channel while also considering disease prevalence, biosimilar activity, pipeline development, product launches, and strategic industry initiatives.

Conclusion

The global anti-inflammatory drugs market is projected to increase from USD 145.05 billion in 2025 to USD 159.26 billion in 2026 and reach USD 336.45 billion by 2034. Rising inflammatory disease prevalence, expanding biologics pipelines, increasing biosimilar adoption, and demand for non-opioid therapies will remain important growth factors. Meanwhile, NSAID safety concerns and increasing competition from biosimilars will continue influencing market strategies.

Unit Value (USD billion)

Segmentation By Drug Class

• Anti-inflammatory Biologics
• Non-steroidal Anti-inflammatory Drugs (NSAIDs)
• Corticosteroids

By Application

• Autoimmune Inflammatory Diseases
  • Rheumatoid Arthritis
  • Psoriasis
  • Others
• Respiratory Diseases
• Others

By Route of Administration

• Oral
• Injection
• Topical
• Inhalation

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Geography

• North America (the U.S. and Canada)
• Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and the Rest of Europe)
• Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and the Rest of Asia- Pacific)
• Latin America (Brazil, Mexico, and the Rest of Latin America)
• Middle East& Africa (South Africa, GCC and the Rest of Middle East & Africa)

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities

4. Key Insights

• 4.1. Prevalence of Major Diseases - For Key Countries
• 4.2. Pipeline Analysis
• 4.3. Patent Snapshot
• 4.4. New Product Launches
• 4.5. Key Industry Developments - Mergers, Acquisitions and Partnerships

5. Global Anti-inflammatory Drugs Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Key Findings / Summary
• 5.2. Market Analysis, Insights and Forecast - By Drug Class
  • 5.2.1. Anti-inflammatory Biologics
  • 5.2.2. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  • 5.2.3. Corticosteroids
• 5.3. Market Analysis, Insights and Forecast - By Application
  • 5.3.1. Autoimmune Inflammatory Diseases
    • 5.3.1.1. Rheumatoid Arthritis
    • 5.3.1.2. Psoriasis
    • 5.3.1.3. Others
  • 5.3.2. Respiratory Diseases
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.4.1. Oral
  • 5.4.2. Injection
  • 5.4.3. Inhalation
  • 5.4.4. Topical
• 5.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.5.1. Hospital Pharmacy
  • 5.5.2. Retail Pharmacy
  • 5.5.3. Online Pharmacy
• 5.6. Market Analysis, Insights and Forecast - By Region
  • 5.6.1. North America
  • 5.6.2. Europe
  • 5.6.3. Asia Pacific
  • 5.6.4. Latin America
  • 5.6.5. Middle East & Africa

6. North America Anti-inflammatory Drugs Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Key Findings / Summary
• 6.2. Market Analysis, Insights and Forecast - By Drug Class
  • 6.2.1. Anti-inflammatory Biologics
  • 6.2.2. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  • 6.2.3. Corticosteroids
• 6.3. Market Analysis, Insights and Forecast - By Application
  • 6.3.1. Autoimmune Inflammatory Diseases
    • 6.3.1.1. Rheumatoid Arthritis
    • 6.3.1.2. Psoriasis
    • 6.3.1.3. Others
  • 6.3.2. Respiratory Diseases
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.4.1. Oral
  • 6.4.2. Injection
  • 6.4.3. Inhalation
  • 6.4.4. Topical
• 6.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.5.1. Hospital Pharmacy
  • 6.5.2. Retail Pharmacy
  • 6.5.3. Online Pharmacy
• 6.6. Market Analysis, Insights and Forecast - By Country
  • 6.6.1. U.S.
  • 6.6.2. Canada

7. Europe Anti-inflammatory Drugs Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Key Findings / Summary
• 7.2. Market Analysis, Insights and Forecast - By Drug Class
  • 7.2.1. Anti-inflammatory Biologics
  • 7.2.2. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  • 7.2.3. Corticosteroids
• 7.3. Market Analysis, Insights and Forecast - By Application
  • 7.3.1. Autoimmune Inflammatory Diseases
    • 7.3.1.1. Rheumatoid Arthritis
    • 7.3.1.2. Psoriasis
    • 7.3.1.3. Others
  • 7.3.2. Respiratory Diseases
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.4.1. Oral
  • 7.4.2. Injection
  • 7.4.3. Inhalation
  • 7.4.4. Topical
• 7.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.5.1. Hospital Pharmacy
  • 7.5.2. Retail Pharmacy
  • 7.5.3. Online Pharmacy
• 7.6. Market Analysis, Insights and Forecast - By Countries/ Sub-region
  • 7.6.1. U.K.
  • 7.6.2. Germany
  • 7.6.3. France
  • 7.6.4. Spain
  • 7.6.5. Italy
  • 7.6.6. Scandinavia
  • 7.6.7. Rest of Europe

8. Asia Pacific Anti-inflammatory Drugs Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Key Findings / Summary
• 8.2. Market Analysis, Insights and Forecast - By Drug Class
  • 8.2.1. Anti-inflammatory Biologics
  • 8.2.2. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  • 8.2.3. Corticosteroids
• 8.3. Market Analysis, Insights and Forecast - By Application
  • 8.3.1. Autoimmune Inflammatory Diseases
    • 8.3.1.1. Rheumatoid Arthritis
    • 8.3.1.2. Psoriasis
    • 8.3.1.3. Others
  • 8.3.2. Respiratory Diseases
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.4.1. Oral
  • 8.4.2. Injection
  • 8.4.3. Inhalation
  • 8.4.4. Topical
• 8.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.5.1. Hospital Pharmacy
  • 8.5.2. Retail Pharmacy
  • 8.5.3. Online Pharmacy
• 8.6. Market Analysis, Insights and Forecast - By Countries/ Sub-region
  • 8.6.1. Japan
  • 8.6.2. China
  • 8.6.3. India
  • 8.6.4. Australia
  • 8.6.5. Southeast Asia
  • 8.6.6. Rest of Asia Pacific

9. Latin America Anti-inflammatory Drugs Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Key Findings / Summary
• 9.2. Market Analysis, Insights and Forecast - By Drug Class
  • 9.2.1. Anti-inflammatory Biologics
  • 9.2.2. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  • 9.2.3. Corticosteroids
• 9.3. Market Analysis, Insights and Forecast - By Application
  • 9.3.1. Autoimmune Inflammatory Diseases
    • 9.3.1.1. Rheumatoid Arthritis
    • 9.3.1.2. Psoriasis
    • 9.3.1.3. Others
  • 9.3.2. Respiratory Diseases
  • 9.3.3. Others
• 9.4. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.4.1. Oral
  • 9.4.2. Injection
  • 9.4.3. Inhalation
  • 9.4.4. Topical
• 9.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.5.1. Hospital Pharmacy
  • 9.5.2. Retail Pharmacy
  • 9.5.3. Online Pharmacy
• 9.6. Market Analysis, Insights and Forecast - By Countries/ Sub regions
  • 9.6.1. Brazil
  • 9.6.2. Mexico
  • 9.6.3. Rest of Latin America

10. Middle East & Africa Anti-inflammatory Drugs Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Key Findings / Summary
• 10.2. Market Analysis, Insights and Forecast - By Drug Class
  • 10.2.1. Anti-inflammatory Biologics
  • 10.2.2. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  • 10.2.3. Corticosteroids
• 10.3. Market Analysis, Insights and Forecast - By Application
  • 10.3.1. Autoimmune Inflammatory Diseases
    • 10.3.1.1. Rheumatoid Arthritis
    • 10.3.1.2. Psoriasis
    • 10.3.1.3. Others
  • 10.3.2. Respiratory Diseases
  • 10.3.3. Others
• 10.4. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.4.1. Oral
  • 10.4.2. Injection
  • 10.4.3. Inhalation
  • 10.4.4. Topical
• 10.5. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.5.1. Hospital Pharmacy
  • 10.5.2. Retail Pharmacy
  • 10.5.3. Online Pharmacy
• 10.6. Market Analysis, Insights and Forecast - By Countries/ Sub region
  • 10.6.1. South Africa
  • 10.6.2. GCC
  • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Key Industry Developments
• 11.2. Global Market Share Analysis (2025)
• 11.3. Company Profiles
  • 11.3.1. AbbVie Inc.
    • 11.3.1.1. Overview,
    • 11.3.1.2. Product & Services,
    • 11.3.1.3. SWOT analysis,
    • 11.3.1.4. Recent developments,
    • 11.3.1.5. strategies,
    • 11.3.1.6. financials (based on availability)
  • 11.3.2. Johnson & Johnson Services, Inc.
    • 11.3.2.1. Overview,
    • 11.3.2.2. Product & Services,
    • 11.3.2.3. SWOT analysis,
    • 11.3.2.4. Recent developments,
    • 11.3.2.5. strategies,
    • 11.3.2.6. financials (based on availability)
  • 11.3.3. Bristol-Myers Squibb Company
    • 11.3.3.1. Overview,
    • 11.3.3.2. Product & Services,
    • 11.3.3.3. SWOT analysis,
    • 11.3.3.4. Recent developments,
    • 11.3.3.5. strategies,
    • 11.3.3.6. financials (based on availability)
  • 11.3.4. Merck & Co., Inc.
    • 11.3.4.1. Overview,
    • 11.3.4.2. Product & Services,
    • 11.3.4.3. SWOT analysis,
    • 11.3.4.4. Recent developments,
    • 11.3.4.5. strategies,
    • 11.3.4.6. financials (based on availability)
  • 11.3.5. Pfizer Inc.
    • 11.3.5.1. Overview,
    • 11.3.5.2. Product & Services,
    • 11.3.5.3. SWOT analysis,
    • 11.3.5.4. Recent developments,
    • 11.3.5.5. strategies,
    • 11.3.5.6. financials (based on availability)
  • 11.3.6. Novartis AG
    • 11.3.6.1. Overview,
    • 11.3.6.2. Product & Services,
    • 11.3.6.3. SWOT analysis,
    • 11.3.6.4. Recent developments,
    • 11.3.6.5. strategies,
    • 11.3.6.6. financials (based on availability)
  • 11.3.7. GlaxoSmithKline plc.
    • 11.3.7.1. Overview,
    • 11.3.7.2. Product & Services,
    • 11.3.7.3. SWOT analysis,
    • 11.3.7.4. Recent developments,
    • 11.3.7.5. strategies,
    • 11.3.7.6. financials (based on availability)
  • 11.3.8. Eli Lilly and Company
    • 11.3.8.1. Overview,
    • 11.3.8.2. Product & Services,
    • 11.3.8.3. SWOT analysis,
    • 11.3.8.4. Recent developments,
    • 11.3.8.5. strategies,
    • 11.3.8.6. financials (based on availability)
  • 11.3.9. Amgen Inc.
    • 11.3.9.1. Overview,
    • 11.3.9.2. Product & Services,
    • 11.3.9.3. SWOT analysis,
    • 11.3.9.4. Recent developments,
    • 11.3.9.5. strategies,
    • 11.3.9.6. financials (based on availability)
  • 11.3.10. Biogen
    • 11.3.10.1. Overview,
    • 11.3.10.2. Product & Services,
    • 11.3.10.3. SWOT analysis,
    • 11.3.10.4. Recent developments,
    • 11.3.10.5. strategies,
    • 11.3.10.6. financials (based on availability)
  • 11.3.11. Other Prominent Players
    • 11.3.11.1. Overview,
    • 11.3.11.2. Product & Services,
    • 11.3.11.3. SWOT analysis,
    • 11.3.11.4. Recent developments,
    • 11.3.11.5. strategies,
    • 11.3.11.6. financials (based on availability)

12. Strategic Recommendations